January 16, 2017 More Chemo May Not Equal Better Outcomes in Ova

http://www.medpagetoday.com/clinical-context/gynecologiccancers/62554

Increasing, the number of cycles of chemotherapy doesn't appear to significantly influence recurrence rates or survival in patients with early stage ovarian clear cell carcinoma (OCCC), according to researchers.

Patients who received 3 cycles of adjuvant chemotherapy had a recurrence rate of 18.4% versus 27.3% for those who received 6 cycles (P= 0.4). Similarly, there was no difference in the impact of 3 cycles of chemotherapy versus 6 on progression-free survival (PFS) or overall survival (OS), even in surgically staged patients, they wrote online in Gynecologic Oncology.